Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution

Autor: Timothy J, Poterucha, Pierre, Elias, Sabahat, Bokhari, Andrew J, Einstein, Albert, DeLuca, Mona, Kinkhabwala, Lynne L, Johnson, Kathleen R, Flaherty, Sunil E, Saith, Jan M, Griffin, Adler, Perotte, Mathew S, Maurer
Rok vydání: 2020
Předmět:
Zdroj: JACC. Cardiovascular imaging. 14(6)
ISSN: 1876-7591
Popis: This study aimed to characterize trends in technetium Tc 99m pyrophosphate (Patients undergoingOver the decade, endomyocardial biopsy rates remained stable with scanning rates peaking at 132 in 2019 (p 0.001). Among 753 patients (516 men, mean age 77 years), 307 (41%) had a visual score of 0, 177 (23%) of 1, and 269 (36%) of 2 or 3. Of 751 patients with analyzable heart to contralateral chest ratios, 249 (33%) had a ratio ≥1.5. Monoclonal protein testing status was assessed in 550 patients, of these, 174 (32%) did not undergo both serum immunofixation and serum free light chain analysis tests, and 331 (60%) did not undergo all 3 tests-serum immunofixation, serum free light chain analysis, and urine protein electrophoresis. Of 196 patients with confirmed ATTR-CA, 143 (73%) had genetic testing for transthyretin mutations. In 103 patients undergoing cardiac biopsy, grades 2 and 3 99mTc-PYP had sensitivity of 94% and specificity of 89% for ATTR-CA with 100% specificity for grade 3 scans. With respect to SPECT as a reference standard, planar imaging had false positive results in 16 of 25 (64%) grade 2 scans.Use of noninvasive testing with
Databáze: OpenAIRE